Tharimmune, Inc. (THAR) 10-Year Financial Performance & Capital Metrics

THAR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutTharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Show more

Revenue $0
EBITDA -$13M -36.1%
Net Income -$12M -30.9%
EPS (Diluted) -9.41 +91.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -233.69% -84.0%
ROIC -
Debt/Equity -
Interest Coverage -908.64 -58.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 80 (top 20%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM4.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM64.16%

ROCE

10Y Avg-403.54%

5Y Avg-403.54%

3Y Avg-403.54%

Latest-238.22%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	994.54K	1.52M	3.21M	6.88M	9.46M	12.43M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	625.81K	671.88K	1.37M	4.6M	5.9M	6.04M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	368.73K	847.27K	1.84M	2.28M	3.56M	6.39M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-994.54K	-1.52M	-3.21M	-6.88M	-9.46M	-12.43M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.53%	-1.11%	-1.15%	-0.37%	-0.32%
EBITDA+	-1.45M	-2.17M	-1.38M	-6.65M	-9.3M	-12.66M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-0.5%	0.37%	-3.84%	-0.4%	-0.36%
D&A (Non-Cash Add-back)	0	0	0	228.49K	152.63K	-222.54K
EBIT	-1.45M	-2.17M	-1.38M	-6.88M	-9.3M	-12.21M
Net Interest Income+	-75.07K	-246.53K	-831.28K	-1.59M	136.13K	236.22K
Interest Income	0	0	0	0	152.63K	249.91K
Interest Expense	75.07K	246.53K	831.28K	1.59M	16.5K	13.68K
Other Income/Expense	-530.93K	-898.22K	1M	-1.59M	136.13K	236.22K
Pretax Income+	-1.53M	-2.42M	-2.21M	-8.47M	-9.32M	-12.2M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-1.53M	-2.42M	-2.21M	-8.47M	-9.32M	-12.2M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.58%	0.09%	-2.84%	-0.1%	-0.31%
Net Income (Continuing)	-1.53M	-2.42M	-2.21M	-8.47M	-9.32M	-12.2M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-55.56	-88.05	-72.81	-280.77	-107.08	-9.41
EPS Growth %	-	-0.58%	0.17%	-2.86%	0.62%	0.91%
EPS (Basic)	-55.56	-88.05	-72.81	-280.77	-107.08	-9.41
Diluted Shares Outstanding	27.45K	27.45K	30.3K	30.18K	87.03K	1.3M
Basic Shares Outstanding	27.45K	27.45K	30.3K	30.18K	87.03K	1.3M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	40.88K	294.8K	621.68K	6.69M	10.95M	3.72M
Cash & Short-Term Investments	38.28K	191.85K	4.36K	6.51M	10.94M	3.56M
Cash Only	38.28K	191.85K	4.36K	6.51M	10.94M	3.56M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	546.65K	178.09K	11.04K	162.26K
Total Non-Current Assets+	0	0	0	0	0	0
Property, Plant & Equipment	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	40.88K	294.8K	621.68K	6.69M	10.95M	3.72M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	6.21%	1.11%	9.76%	0.64%	-0.66%
Total Current Liabilities+	1.13M	2.73M	4.53M	1.14M	1.82M	2.41M
Accounts Payable	241.41K	514.83K	1.46M	954.5K	908.58K	1.09M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	430.6K	563.42K	1.39M	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	126.18K	1.33M	980.23K	0	0	1.32M
Current Ratio	0.04x	0.11x	0.14x	5.84x	6.03x	1.54x
Quick Ratio	0.04x	0.11x	0.14x	5.84x	6.03x	1.54x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	532.77K	1.29M	772.9K	0	0	0
Long-Term Debt	532.77K	1.29M	772.9K	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	1.66M	4.01M	5.31M	1.14M	1.82M	2.41M
Total Debt+	963.37K	1.85M	2.17M	0	0	0
Net Debt	925.09K	1.66M	2.16M	-6.51M	-10.94M	-3.56M
Debt / Equity	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-13.25x	-6.16x	-3.86x	-4.32x	-572.87x	-908.64x
Total Equity+	-1.62M	-3.72M	-4.68M	5.54M	9.13M	1.31M
Equity Growth %	-	-1.29%	-0.26%	2.18%	0.65%	-0.86%
Book Value per Share	-59.09	-135.41	-154.59	183.70	104.92	1.01
Total Shareholders' Equity	-1.62M	-3.72M	-4.68M	5.54M	9.13M	1.31M
Common Stock	628	636	636	46	1.18K	198
Retained Earnings	-2.09M	-4.7M	-6.91M	-15.38M	-24.7M	-36.9M
Treasury Stock	0	0	0	-69.97K	-69.97K	-69.97K
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-706.11K	-1.08M	-1.09M	-6.56M	-7.3M	-10.9M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.53%	-0.01%	-5.04%	-0.11%	-0.49%
Net Income	-1.53M	-2.42M	-2.21M	-8.47M	-9.32M	-12.2M
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	0	234.58K	1.24M	800.7K	831.86K	710.31K
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	576.67K	797.04K	-1.17M	1.68M	350K	20.55K
Working Capital Changes	242.69K	307.32K	1.05M	-569.11K	837.13K	564.71K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	15.76K	306.57K	580.85K	-141.17K	-45.93K	181.09K
Cash from Investing+	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	708.38K	1.23M	898.75K	13.06M	11.72M	3.53M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	-179.27K	-521.29K	-510K	-661.73K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-706.11K	-1.08M	-1.09M	-6.56M	-7.3M	-10.9M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.53%	-0.01%	-5.04%	-0.11%	-0.49%
FCF per Share	-25.72	-39.28	-35.84	-217.31	-83.88	-8.41
FCF Conversion (FCF/Net Income)	0.46x	0.45x	0.49x	0.77x	0.78x	0.89x
Interest Paid	0	0	0	0	16.5K	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-1973.37%	-127.01%	-233.69%
Interest Coverage	-13.25x	-6.16x	-3.86x	-4.32x	-572.87x	-908.64x
FCF Conversion	0.46x	0.45x	0.49x	0.77x	0.78x	0.89x

Frequently Asked Questions

Growth & Financials

Tharimmune, Inc. (THAR) grew revenue by 0.0% over the past year. Growth has been modest.

Tharimmune, Inc. (THAR) reported a net loss of $10.3M for fiscal year 2024.

Dividend & Returns

Tharimmune, Inc. (THAR) has a return on equity (ROE) of -233.7%. Negative ROE indicates the company is unprofitable.

Tharimmune, Inc. (THAR) had negative free cash flow of $8.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener